Claims
- 1. A compound of the formula (I) whereR1 and R2 together with the formal double bond bridging them form a phenyl ring or a six-membered aromatic heterocycle having 1 or 2 nitrogen atoms, which is optionally substituted by halogen, nitro, cyano, trifluoromethyl, hydroxyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl, amino, carboxyl, phenoxy, (C6-C10)-aryl, (C1-C6)-alkylamino, (C1-C6)-alkylsulfone or a group of the formula —SO2NRaRb wherein Ra and Rb may independently represent hydrogen or (C1-C6)-alkyl, and R3=H or (C1-C4)-alkyl, and A=O,S, (CH2)n where n=1,2,3 or 4 or N—R7 where R7=H or (C1-C4)-alkyl, or is absent and X, Y, Z=O, S, N, N—R8 where R8=H, (C1-C6)-alkyl or (C6-C10)-aryl, or C—(R9)(R10) where R9, R10=H, (C1-C6)-alkyl or (C1-C10)-aryl, or C—(R11) if the X, Y or Z in question is participating in a formal double bond, where R11=H, (C1-C6)-alkyl or (C6-C10)-aryl, and D=O, S, (CH2)n where n=1,2,3 or 4, or N—R7 where R7=H or (C1-C4)-alkyl, or is absent and E, G, L=H, halogen, nitro, cyano, trifluoromethyl, hydroxyl, carboxyl, (C1-C6)-alkyl, (C1-C6)-alkoxy or (C1-C6)-alkoxycarbonyl, where E, G and L can be identical or different and R4=H, (C3-C8)-cycloalkyl, (C1-C6)-alkyl, which is optionally substituted by hydroxyl, (C1-C6)-alkoxy or phenyl, where the latter is optionally in turn substituted on the phenyl ring by halogen, (C1-C4)-alkyl, (C1-C4)-alkoxy, hydroxyl, trifluoromethoxy or trifluoromethyl, and R5=H or (C1-C4)-alkyl and R6=H, (C1-C6)-alkyl or benzyl, or a pharmaceutically acceptable salt thereof.
- 2. A compound of the formula (I) as claimed in claim 1, whereinR1 and R2 together with the formal double bond bridging them form a phenyl ring or a six-membered aromatic heterocycle having 1 or 2 nitrogen atoms, which is optionally substituted by (C1-C6)-alkoxy, nitro or amino, and R3=H, and A=O, S, (CH2)n where n=1,2,3 or 4 or N—H, or is absent and X, Y, Z=O, S, N, N—R8 where R8=H, (C1-C6)-alkyl or (C6-C10)-aryl, or C—(R9)(R10) where R9, R10=H, (C1-C6)-alkyl or (C6-C10)-aryl, or C—(R11) if the X, Y or Z in question is participating in a formal double bond, where R11=H, (C1-C6)-alkyl or (C6-C10)-aryl, and D=O, S, (CH2)n where n=1, 2, 3 or 4, or N—H, or is absent and E, G, L=H, and R4=H, benzyl, cyclopropyl, cyclopentyl, cyclohexyl, phenylethyl or (C1-C4)-alkyl, which is optionally substituted by hydroxyl or methoxy, and R5=H, and R6=H or methyl, or a pharmaceutically acceptable salt thereof.
- 3. The compound of formula (I) according to claim 1, whereinR1 and R2 together with the formal double bond bridging them form a phenyl ring, which is optionally substituted by nitro and R3=H and A=is absent and X=N, Y=O and Z=N or X=N, Y=N and Z=O, S or X=CH2, Y=O, Z=N, and D=is absent and E, G, L=H, and R4=methyl, cyclopropyl or (C1-C4)-alkyl substituted by methoxy and R5=H, and R6=H or methyl, or a pharmaceutically acceptable salt thereof.
- 4. A method of treating osteoporosis, carinoses, and/or atherosclerosis in a mammal, comprising administering to said mammal an effective amount of a compound according to claim 1.
- 5. A pharmaceutical composition comprising one or more compounds of the formula (I) as claimed in claim 1 and a pharmaceutical auxiliary.
Parent Case Info
This application is a divisional of Ser. No. 09/211,274, filed on Dec. 14, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/EP99/09525 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/35917 |
6/22/2000 |
WO |
A |
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5403836 |
Blackburn et al. |
Apr 1995 |
A |
5668159 |
Jin et al. |
Sep 1997 |
A |
Foreign Referenced Citations (5)
Number |
Date |
Country |
9414776 |
Jul 1994 |
WO |
9514683 |
Jun 1995 |
WO |
9600730 |
Jan 1996 |
WO |
9626190 |
Aug 1996 |
WO |
9724119 |
Jul 1997 |
WO |